India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment

Feb 12 (Reuters) - India's Zydus Lifesciences ZYDU.NS said on Thursday that it and its U.S. unit have agreed to pay $120 million to Astellas Pharma 4503.T as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder drug Mirabegron.

Zydus and its unit will also pay a pre-paid per‑unit licensing fee on sales of its generic Mirabegron in the U.S. from the date of the agreement until September 2027, the company said.